Literature DB >> 22588430

Demographic and clinical features of gout patients in Turkey: a multicenter study.

Mehmet Akif Öztürk1, Arif Kaya, Soner Şenel, Salim Dönmez, Ayşe Balkarlı, Veli Çobankara, Çiğdem Erhan, Mehmet Sayarlıoğlu, Yunus Ugan, Ş Ercan Tunç, Yavuz Pehlivan, Bünyamin Kısacık, Abdurrahman Tufan, Ahmet Mesut Onat, Engin Tezcan, Gözde Yıldırım Çetin, Omer Nuri Pamuk.   

Abstract

Gout results from multifactor interactions between gender, age, genetic and environmental factors. Environmental factors underlying gout and precipitating factors triggering acute attacks might vary in different populations with different lifestyles. In this study, we aimed to collect data regarding the demographic and clinical features, comorbid factors, and precipitating factors associated with the initiation of acute attacks in gout patients in Turkey. A total of 312 patients were included in this study (mean age, 58.8 ± 13.8 years; female/male ratio, 55/257). The demographic features, alcohol intake, clinical and laboratory features, and comorbid conditions including obesity, diabetes mellitus, hyperlipidemia, hypertension, and coronary heart disease were noted in a standard questionnaire. Precipitating factors initiating acute attacks (if any) were also noted. The patients were divided into 4 groups according to the region of location as central Anatolian region, southeast Anatolian region, Aegean region, and Trakya region. Our results were compared according to the gender and the location of the patients. The mean age at the start of the symptoms was 10 years higher in women (60.4 ± 14.8 and 50.6 ± 13.5 years in women and men, respectively, p < 0.001).Obesity was present in 40.1 %, diabetes mellitus in 17.9 %, hyperlipidemia in 30.1 %, hypertension in 53.5 %, coronary artery disease in 17 %, and nephrolithiasis in 21.8 % of patients. Precipitating factors triggering gout flares were as follows: diet (high consumption of meat or fish) in 46.5 %, alcohol consumption in 15.7 %, diuretics in 8.3 %, diet or diuretics in 5.1 %, diet or alcohol in 4.5 %, diet or alcohol or diuretics in 1.6 %, others in 4.2 %, and none in 14.1 %. The presence of diabetes and diuretic use was more common among women. Use of diuretics is a more common trigger for gout flares among women. On the other hand, various comorbid conditions, such as obesity and hypertension, and triggers for gout flares may differ between patients living in different geographic regions. In summary, we reported the first data regarding clinical and demographic characteristics of gout in Turkey. The majority of our patients could describe at least one "trigger" that initiated gout flare. Both comorbid conditions and triggers of attack might differ between men and women, and in different geographic areas. Better knowledge of the modifiable risk factors can be useful for the management strategy to optimize long-term patient outcomes in local clinics.

Entities:  

Mesh:

Year:  2012        PMID: 22588430     DOI: 10.1007/s00296-012-2442-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  23 in total

1.  Alcohol consumption as a trigger of recurrent gout attacks.

Authors:  Yuqing Zhang; Ryan Woods; Christine E Chaisson; Tuhina Neogi; Jingbo Niu; Timothy E McAlindon; David Hunter
Journal:  Am J Med       Date:  2006-09       Impact factor: 4.965

2.  Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study.

Authors:  David J Hunter; Michael York; Christine E Chaisson; Ryan Woods; Jingbo Niu; Yuqing Zhang
Journal:  J Rheumatol       Date:  2006-06-01       Impact factor: 4.666

Review 3.  Epidemiology of hyperuricemia and gout.

Authors:  Andrew J Luk; Peter A Simkin
Journal:  Am J Manag Care       Date:  2005-11       Impact factor: 2.229

4.  Frequency and risk factors of gout flares in a large population-based cohort of incident gout.

Authors:  Dietrich Rothenbacher; Paola Primatesta; Alberto Ferreira; Lucía Cea-Soriano; Luis A García Rodríguez
Journal:  Rheumatology (Oxford)       Date:  2011-01-12       Impact factor: 7.580

5.  Sex differences in gout epidemiology: evaluation and treatment.

Authors:  L R Harrold; R A Yood; T R Mikuls; S E Andrade; J Davis; J Fuller; K A Chan; D Roblin; M A Raebel; A Von Worley; R Platt; K G Saag
Journal:  Ann Rheum Dis       Date:  2006-04-27       Impact factor: 19.103

6.  Gout medication treatment patterns and adherence to standards of care from a managed care perspective.

Authors:  Chaitanya A Sarawate; Kathleen K Brewer; Wenya Yang; Pankaj A Patel; H Ralph Schumacher; Kenneth G Saag; Alan W Bakst
Journal:  Mayo Clin Proc       Date:  2006-07       Impact factor: 7.616

7.  Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting.

Authors:  Aylin Altan Riedel; Mike Nelson; Katrine Wallace; Nancy Joseph-Ridge; Michele Cleary; Adel G Fam
Journal:  J Clin Rheumatol       Date:  2004-12       Impact factor: 3.517

8.  Purine-rich foods, dairy and protein intake, and the risk of gout in men.

Authors:  Hyon K Choi; Karen Atkinson; Elizabeth W Karlson; Walter Willett; Gary Curhan
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

9.  Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?

Authors:  Eric Q Wu; Pankaj A Patel; Reema R Mody; Andrew P Yu; Kevin E Cahill; Jackson Tang; Eswar Krishnan
Journal:  J Rheumatol       Date:  2009-04-15       Impact factor: 4.666

10.  Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005.

Authors:  L Annemans; E Spaepen; M Gaskin; M Bonnemaire; V Malier; T Gilbert; G Nuki
Journal:  Ann Rheum Dis       Date:  2007-11-02       Impact factor: 19.103

View more
  8 in total

Review 1.  Meat consumption and gout: Friend, foe or neither?

Authors:  Giuseppe Lippi; Camilla Mattiuzzi; Gianfranco Cervellin
Journal:  Rheumatol Int       Date:  2015-03-21       Impact factor: 2.631

Review 2.  An old disease with new insights: Update on diagnosis and treatment of gout.

Authors:  Berivan Bitik; M Akif Öztürk
Journal:  Eur J Rheumatol       Date:  2014-06-01

3.  Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study.

Authors:  Minning Shen; Junyu Zhang; Kai Qian; Chunmei Li; Wenyu Xu; Bingjie Gu; Xiaoqin Wang; Qijie Ren; Leilei Yang; Hai Yuan; Dinglei Su; Xingguo Chen
Journal:  Clin Rheumatol       Date:  2018-09-09       Impact factor: 2.980

Review 4.  Gout: a review of nonmodifiable and modifiable risk factors.

Authors:  Lindsey A MacFarlane; Seoyoung C Kim
Journal:  Rheum Dis Clin North Am       Date:  2014-09-02       Impact factor: 2.670

5.  The management of gout in different clinical specialties in Turkey: a patient-based survey.

Authors:  Mehmet Akif Öztürk; Rıdvan Mercan; Kevser Gök; Ahmet Mesut Onat; Bünyamin Kısacık; Gezmiş Kimyon; Ayşe Balkarlı; Arif Kaya; Veli Çobankara; Mehmet Ali Balcı; ÖmerNuri Pamuk; Gözde Yıldırım Çetin; Mehmet Sayarlıoğlu; Soner Şenel; Mehmet Engin Tezcan; Adem Küçük; Kemal Üreten; Şafak Şahin; Abdurrahman Tufan
Journal:  Clin Rheumatol       Date:  2016-10-08       Impact factor: 2.980

6.  The relationship between ferritin and urate levels and risk of gout.

Authors:  Tahzeeb Fatima; Cushla McKinney; Tanya J Major; Lisa K Stamp; Nicola Dalbeth; Cory Iverson; Tony R Merriman; Jeffrey N Miner
Journal:  Arthritis Res Ther       Date:  2018-08-15       Impact factor: 5.156

7.  Cut-Off Value of Serum Uric Acid for Development of Gout Disease in Patients with Multiple Co-Morbidities.

Authors:  Firdevs Ulutaş; Aslı Bozdemir; Nevzat Atalay Çelikyürek; Canan Albayrak Yaşar; Veli Çobankara
Journal:  Mediterr J Rheumatol       Date:  2021-09-30

8.  Older age and diclofenac are associated with increased risk of upper gastrointestinal bleeding in gout patients.

Authors:  Wan Syamimee Wan Ghazali; Wan Mohd Khairul Bin Wan Zainudin; Nurul Khaiza Yahya; Asmahan Mohamed Ismail; Kah Keng Wong
Journal:  PeerJ       Date:  2021-05-20       Impact factor: 2.984

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.